IN2014DN10670A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN10670A IN2014DN10670A IN10670DEN2014A IN2014DN10670A IN 2014DN10670 A IN2014DN10670 A IN 2014DN10670A IN 10670DEN2014 A IN10670DEN2014 A IN 10670DEN2014A IN 2014DN10670 A IN2014DN10670 A IN 2014DN10670A
- Authority
- IN
- India
- Prior art keywords
- compound
- treating
- formula
- methods
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660428P | 2012-06-15 | 2012-06-15 | |
| US201261678795P | 2012-08-02 | 2012-08-02 | |
| PCT/US2013/045919 WO2013188783A1 (en) | 2012-06-15 | 2013-06-14 | Deuterated derivatives of ruxolitinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10670A true IN2014DN10670A (en:Method) | 2015-08-28 |
Family
ID=48699982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10670DEN2014 IN2014DN10670A (en:Method) | 2012-06-15 | 2013-06-14 |
Country Status (19)
| Country | Link |
|---|---|
| US (7) | US20150197525A1 (en:Method) |
| EP (4) | EP3882249B1 (en:Method) |
| AU (3) | AU2013274030B2 (en:Method) |
| BR (1) | BR122023027277A2 (en:Method) |
| CA (1) | CA2876306C (en:Method) |
| DK (2) | DK3450434T3 (en:Method) |
| EA (1) | EA201492287A1 (en:Method) |
| ES (2) | ES3037872T3 (en:Method) |
| FI (1) | FI3882249T3 (en:Method) |
| HR (1) | HRP20250965T1 (en:Method) |
| IN (1) | IN2014DN10670A (en:Method) |
| LT (1) | LT3882249T (en:Method) |
| MX (2) | MX360495B (en:Method) |
| PL (2) | PL3882249T3 (en:Method) |
| PT (1) | PT3882249T (en:Method) |
| RS (1) | RS67061B1 (en:Method) |
| SI (1) | SI3882249T1 (en:Method) |
| SM (1) | SMT202500302T1 (en:Method) |
| WO (1) | WO2013188783A1 (en:Method) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2343299T1 (sl) | 2005-12-13 | 2016-06-30 | Incyte Holdings Corporation | S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b) pirimidini kot zaviralci janus kinaze |
| CA2792508C (en) | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| SI3882249T1 (sl) | 2012-06-15 | 2025-10-30 | Sun Pharmaceutical Industries, Inc. | Devterirani derivati ruksolitiniba |
| IL291391B (en) | 2012-11-15 | 2022-11-01 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| EP3030227B1 (en) | 2013-08-07 | 2020-04-08 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
| WO2015184087A2 (en) * | 2014-05-28 | 2015-12-03 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| WO2016196961A1 (en) | 2015-06-03 | 2016-12-08 | Uwm Research Foundation, Inc. | Ligands selective to alpha 6 subunit-containing gabaa receptors ans their methods of use |
| CN108697700B (zh) | 2016-02-04 | 2021-08-17 | 辛多美制药有限公司 | 氘代多潘立酮组合物和用于治疗病症的方法 |
| CA3014275A1 (en) * | 2016-02-12 | 2017-08-17 | Vertex Pharmaceuticals (Europe) Limited | Deuterium-modified cftr modulators |
| RS66006B1 (sr) * | 2016-05-04 | 2024-10-31 | Sun Pharmaceutical Industries Inc | Lečenјe poremećaja opadanјa kose deuterisanim jak inhibitorima |
| WO2018112245A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices |
| KR20240125702A (ko) | 2017-06-30 | 2024-08-19 | 신돔 파마, 인크. | 중수소화 돔페리돈 조성물, 방법, 및 제조 |
| US20200353419A1 (en) | 2017-11-22 | 2020-11-12 | Dauntless 1, Inc. | Membrane emulsification device for microsphere creation |
| EP3713545A1 (en) | 2017-11-22 | 2020-09-30 | Dauntless 1, Inc. | Therapeutic compound formulations |
| US11179412B2 (en) * | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| US20210002374A1 (en) | 2018-03-08 | 2021-01-07 | Novartis Ag | USE OF an anti-P-selectin antibody |
| UA127925C2 (uk) | 2018-03-30 | 2024-02-14 | Інсайт Корпорейшн | Лікування гнійного гідраденіту з використанням інгібіторів jak |
| JP7565798B2 (ja) | 2018-03-30 | 2024-10-11 | インサイト・コーポレイション | 炎症性皮膚疾患のバイオマーカー |
| AU2019252259A1 (en) | 2018-04-13 | 2020-12-03 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
| EP3921318A1 (en) * | 2019-02-06 | 2021-12-15 | Concert Pharmaceuticals Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| CA3132371A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| EP3941474A2 (en) | 2019-03-19 | 2022-01-26 | Incyte Corporation | Biomarkers for vitiligo |
| US11731947B2 (en) | 2019-04-10 | 2023-08-22 | University Of Notre Dame Du Lac | Deuterated antimicrobial compounds |
| WO2020223640A1 (en) | 2019-05-02 | 2020-11-05 | Intel Corporation | Quality of service (qos) in information centric networking (icn) |
| WO2020236950A1 (en) | 2019-05-21 | 2020-11-26 | Dauntless 1, Inc. | Therapeutic microsphere formulations containing charged polymers |
| WO2021053490A1 (en) | 2019-09-16 | 2021-03-25 | Novartis Ag | Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis |
| JP2022547311A (ja) | 2019-09-16 | 2022-11-11 | ノバルティス アーゲー | 骨髄線維症の治療のためのｍｄｍ２阻害剤の使用 |
| WO2021062163A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| US12203942B2 (en) | 2019-10-10 | 2025-01-21 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US12360120B2 (en) | 2019-10-10 | 2025-07-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| JP7518900B2 (ja) | 2019-10-16 | 2024-07-18 | インサイト・コーポレイション | 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用 |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| CN112791078B (zh) | 2019-11-13 | 2022-12-06 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| PH12022551052A1 (en) | 2019-11-22 | 2023-05-29 | Incyte Corp | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
| JP2023528223A (ja) | 2020-05-13 | 2023-07-04 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体 |
| WO2021236139A1 (en) | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| US20230322787A1 (en) | 2020-08-12 | 2023-10-12 | Concert Pharmaceuticals, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| US20240000777A1 (en) | 2020-10-08 | 2024-01-04 | Novartis Ag | Use of an erk inhibitor for the treatment of myelofibrosis |
| IL302401A (en) | 2020-10-28 | 2023-06-01 | Sun Pharmaceutical Ind Inc | Regimens for the treatment of hair loss disorders with deuterated jak inhibitors |
| US20230404917A1 (en) * | 2020-11-19 | 2023-12-21 | Sol-Gel Technologies Ltd. | Ruxolitinib or deuterated ruxolitinib composition and uses thereof |
| PT4255442T (pt) | 2020-12-04 | 2025-05-19 | Incyte Corp | Inibidor de jak com um análogo da vitamina d para o tratamento de doenças da pele |
| WO2022150676A1 (en) | 2021-01-11 | 2022-07-14 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
| CN114853760A (zh) * | 2021-02-03 | 2022-08-05 | 南京正大天晴制药有限公司 | 一种芦可替尼中间体的制备方法 |
| CN118159272A (zh) | 2021-08-11 | 2024-06-07 | 太阳医药工业公司 | 用氘化的jak抑制剂来治疗脱发病症 |
| CA3228509A1 (en) | 2021-08-12 | 2023-02-16 | Sun Pharmaceutical Industries, Inc. | Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors |
| CN113820413B (zh) * | 2021-09-17 | 2023-04-07 | 重庆华邦胜凯制药有限公司 | 高效液相色谱法分离测定磷酸芦可替尼及杂质的方法 |
| EP4518863A1 (en) | 2022-05-04 | 2025-03-12 | Sun Pharmaceutical Industries, Inc. | Dosage regimens for treatment with deuterated jak inhibitors |
| CN117384163A (zh) * | 2022-07-05 | 2024-01-12 | 盛世泰科生物医药技术(苏州)股份有限公司 | 一种含偕二氟基的化合物及其制备方法和用途 |
| WO2024196761A1 (en) * | 2023-03-17 | 2024-09-26 | Mayo Foundation For Medical Education And Research | Use of oral jak kinase inhibitors to treat lichen planus |
| WO2024194352A1 (en) | 2023-03-23 | 2024-09-26 | Glaxosmithkline Intellectual Property (No.3) Limited | Deuterated p2x3 modulators |
| US12364699B2 (en) | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
| US12247034B1 (en) | 2024-04-19 | 2025-03-11 | Sun Pharmaceutical Industries, Inc. | Crystalline form of deuruxolitinib phosphate |
| WO2025226637A1 (en) | 2024-04-22 | 2025-10-30 | Incyte Corporation | Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| DE69535592T2 (de) | 1994-03-25 | 2008-06-12 | Isotechnika, Inc., Edmonton | Verbesserung der effektivität von arzneimitteln duren deuterierung |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| DE60001623T2 (de) * | 1999-12-03 | 2003-12-18 | Pfizer Products Inc., Groton | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| NZ528689A (en) | 2001-05-03 | 2005-03-24 | F | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| US6737042B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| KR20070083839A (ko) | 2004-09-29 | 2007-08-24 | 코디스 코포레이션 | 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태 |
| CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| SI2343299T1 (sl) | 2005-12-13 | 2016-06-30 | Incyte Holdings Corporation | S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b) pirimidini kot zaviralci janus kinaze |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| US20080103122A1 (en) * | 2006-09-05 | 2008-05-01 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| JP2011510079A (ja) | 2008-01-22 | 2011-03-31 | コンサート ファーマシューティカルズ インコーポレイテッド | ゲフィチニブ誘導体 |
| JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| SI3882249T1 (sl) | 2012-06-15 | 2025-10-30 | Sun Pharmaceutical Industries, Inc. | Devterirani derivati ruksolitiniba |
| IL291391B (en) * | 2012-11-15 | 2022-11-01 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
-
2013
- 2013-06-14 SI SI201332107T patent/SI3882249T1/sl unknown
- 2013-06-14 HR HRP20250965TT patent/HRP20250965T1/hr unknown
- 2013-06-14 WO PCT/US2013/045919 patent/WO2013188783A1/en not_active Ceased
- 2013-06-14 EP EP21156398.6A patent/EP3882249B1/en active Active
- 2013-06-14 DK DK18188152.5T patent/DK3450434T3/da active
- 2013-06-14 FI FIEP21156398.6T patent/FI3882249T3/fi active
- 2013-06-14 BR BR122023027277-3A patent/BR122023027277A2/pt not_active Application Discontinuation
- 2013-06-14 ES ES21156398T patent/ES3037872T3/es active Active
- 2013-06-14 IN IN10670DEN2014 patent/IN2014DN10670A/en unknown
- 2013-06-14 CA CA2876306A patent/CA2876306C/en active Active
- 2013-06-14 AU AU2013274030A patent/AU2013274030B2/en active Active
- 2013-06-14 LT LTEP21156398.6T patent/LT3882249T/lt unknown
- 2013-06-14 ES ES18188152T patent/ES2867048T3/es active Active
- 2013-06-14 PT PT211563986T patent/PT3882249T/pt unknown
- 2013-06-14 PL PL21156398.6T patent/PL3882249T3/pl unknown
- 2013-06-14 PL PL18188152T patent/PL3450434T3/pl unknown
- 2013-06-14 EP EP18188152.5A patent/EP3450434B1/en active Active
- 2013-06-14 DK DK21156398.6T patent/DK3882249T3/da active
- 2013-06-14 MX MX2014015185A patent/MX360495B/es active IP Right Grant
- 2013-06-14 RS RS20250758A patent/RS67061B1/sr unknown
- 2013-06-14 EP EP25175288.7A patent/EP4606434A2/en active Pending
- 2013-06-14 EP EP13732046.1A patent/EP2861600A1/en not_active Withdrawn
- 2013-06-14 MX MX2018013542A patent/MX373123B/es unknown
- 2013-06-14 EA EA201492287A patent/EA201492287A1/ru unknown
- 2013-06-14 SM SM20250302T patent/SMT202500302T1/it unknown
-
2014
- 2014-12-15 US US14/570,954 patent/US20150197525A1/en not_active Abandoned
-
2015
- 2015-05-08 US US14/707,912 patent/US9249149B2/en active Active
-
2016
- 2016-10-05 AU AU2016238877A patent/AU2016238877B2/en active Active
-
2017
- 2017-03-09 US US15/454,844 patent/US20170239254A1/en not_active Abandoned
-
2018
- 2018-11-26 AU AU2018271227A patent/AU2018271227B2/en active Active
-
2019
- 2019-03-11 US US16/298,795 patent/US20190308976A1/en not_active Abandoned
-
2020
- 2020-12-10 US US17/118,050 patent/US20210330674A1/en not_active Abandoned
-
2022
- 2022-12-09 US US18/078,571 patent/US20230355629A1/en active Pending
-
2024
- 2024-10-03 US US18/905,925 patent/US20250025467A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10670A (en:Method) | ||
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| IN2015DN01156A (en:Method) | ||
| PH12015500064B1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| PH12014501273A1 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
| MX2015002040A (es) | Baricitinib deuterado. | |
| IN2014MN02598A (en:Method) | ||
| IN2015DN00598A (en:Method) | ||
| MY184303A (en) | Notch pathway signaling inhibitor compound | |
| MY199131A (en) | Human plasma kallikrein inhibitors | |
| GB201106750D0 (en) | Novel compounds | |
| SG194469A1 (en) | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | |
| IL234884A0 (en) | Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use | |
| PH12018500446A1 (en) | Pyridinone dicarboxamide for use as bromodomain inhibitors | |
| IN2014DN06869A (en:Method) | ||
| MX362879B (es) | Usos novedosos. | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| MX2016004934A (es) | Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia. | |
| IN2014DN07996A (en:Method) | ||
| EA201270728A1 (ru) | Пуриновые соединения | |
| MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
| IN2014DN03010A (en:Method) | ||
| MX2015007945A (es) | Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. | |
| PH12016500809B1 (en) | Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors |